HC Wainwright Reaffirms Neutral Rating for Co-Diagnostics (NASDAQ:CODX)

Co-Diagnostics (NASDAQ:CODX)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

Several other research analysts have also weighed in on CODX. Weiss Ratings restated a “sell (d-)” rating on shares of Co-Diagnostics in a research report on Thursday, October 30th. D. Boral Capital restated a “buy” rating and issued a $3.00 price target on shares of Co-Diagnostics in a report on Tuesday, October 28th. Finally, Wall Street Zen raised Co-Diagnostics to a “hold” rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $2.00.

Co-Diagnostics Price Performance

Co-Diagnostics stock opened at $0.33 on Monday. The stock’s 50 day moving average price is $0.40 and its 200 day moving average price is $0.33. Co-Diagnostics has a 1-year low of $0.23 and a 1-year high of $1.55. The company has a market cap of $19.79 million, a PE ratio of -0.33 and a beta of 0.98.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.30 million. Co-Diagnostics had a negative net margin of 6,347.34% and a negative return on equity of 70.26%. On average, equities research analysts anticipate that Co-Diagnostics will post -1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Co-Diagnostics stock. Jane Street Group LLC grew its holdings in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 166,254 shares of the company’s stock after purchasing an additional 126,105 shares during the quarter. Jane Street Group LLC owned approximately 0.50% of Co-Diagnostics worth $47,000 at the end of the most recent quarter. Institutional investors own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.